To evaluate the clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer.

A retrospective analysis was conducted on 88 patients with advanced rectal cancer admitted from January 2019 to January 2021.Patients were categorized into two groups based on their treatment regimens: the control group(treated with bevacizumab combined with oxaliplatin, n=47)and the observation group(treated with anlotinib combined with oxaliplatin, n=41). Clinical efficacy after treatment, serum tumor markers(CEA and CA19-9)levels, quality of life, and adverse reaction incidence were compared between the two groups.Both groups were also followed up for 2 years to observe survival status.

After treatment, the objective response rate(ORR)of the observation group was 46.34%, and the disease control rate(DCR)was 78.05%, both significantly higher than those of the control group(ORR 25.53% and DCR 57.45%, P<0.05). After treatment, serum tumor markers CEA and CA19-9 both showed significant improvement, and the improvement in the observation group was significantly better than that in the control group(P<0.001). During the 2-year follow-up period, the median progression-free survival(PFS)of the observation group was(19.88±5.12)months, significantly longer than that of the control group, which was(16.91±6.06)months(P<0.05). In terms of quality of life, the scores of physical condition, family/social situation, emotional state, functional status, and additional concerns in the observation group were all significantly higher than those in the control group(P<0.05). Moreover, there was no significantly significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).

Anlotinib combined with oxaliplatin demonstrates greater clinical efficacy for treating advanced rectal cancer than bevacizumab combined with oxaliplatin, which can further prolong the median PFS of patients and improve their quality of life.